COMMUNIQUÉS West-GlobeNewswire
-
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
17/09/2024 - 17:45 -
EssilorLuxottica: Déclaration de transactions sur actions propres
17/09/2024 - 18:00 -
EssilorLuxottica dévoile son futur siège social à Paris
17/09/2024 - 18:45 -
EssilorLuxottica unveils plans for its new corporate headquarters in Paris
17/09/2024 - 18:45 -
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
17/09/2024 - 18:55 -
Inteleos Donates 49 Laptops to Annapolis Trust, Empowering Disadvantaged Students with Technology Skills
17/09/2024 - 19:03 -
Move Health Holdings Corp. and No Fear Counselling Corp. Complete Merger Transaction
17/09/2024 - 19:19 -
Fairway Consulting Group Appoints Brennan Clark as Vice President of Executive Search
17/09/2024 - 19:25 -
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
17/09/2024 - 13:30 -
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
17/09/2024 - 13:30 -
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
17/09/2024 - 13:30 -
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
17/09/2024 - 13:30 -
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
17/09/2024 - 14:00 -
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
17/09/2024 - 14:00 -
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
17/09/2024 - 14:00 -
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
17/09/2024 - 14:00 -
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
17/09/2024 - 14:00 -
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
17/09/2024 - 14:00 -
Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients
17/09/2024 - 14:00
Pages